Banking & Benifits
Using Stem Cells to Treat Diseases
Cord blood stem cells has been expensively used for therapies as compared to any other sources due to its ready availability and nascent nature delivering better results post therapy. Apart from this the lesser matching required for a therapy using cord blood stem cells as compared to other sources of haemopoetic stem cells makes it the choice of every therapist minimizing the risk associated post therapy. Around 25 years ago, the first human transplant using umbilical cord blood stem cells was performed. At the time, only one disease was treatable using cord blood stem cells. Today, cord blood stem cells can be used in the treatment of nearly 80 diseases and the list continues to develop. Cord blood stem cells have proven track records on treatment of diseases like Thalassemia, Leukemia, Anaemia, Cerebral palsy, Diabetes and various, Blood disorders, Bone marrow syndromes, Cancers, Hemoglobinopathies, Immunodeficiencies, Metabolic disorders. Further more than 300 diseases and conditions are in research progressing towards positive results. New medical technology may well use these cells to rebuild cardiac tissue, repair damage due to stroke or spinal cord injuries and reverse the effects of such diseases as multiple sclerosis or Parkinson’s. While the research is still in its early stages, the possibilities are extremely promising. And, banking your child’s stem cells increases access to any of these technologies in the future
Acute Leukemia
Acute Lymphoblastic Leukemia (ALL)
Acute Myelogenous Leukemia (AML)
Acute Biphenotypic Leukemia
Acute Undifferentiated Leukemia
Chronic Leukemia
Acute Myelofibrosis
Agnogenic Myeloid Metaplasia (myelofibrosis)
Polycythemia Vera
Essential Thrombocythemia
Myelodysplastic Syndromes
Chronic Myelogenous Leukemia (CML)
Chronic Lymphocytic Leukemia (CLL)
Juvenile Chronic Myelogenous Leukemia (JCML)
Juvenile Myelomonocytic Leukemia (JMML)
Phagocyte Disorders
Chediak-Higashi Syndrome
Chronic Granulomatous Disease
Neutrophil Actin Deficiency
Reticular Dysgenesis
Inherited Metabolic Disorders
Mucopolysaccharidoses (MPS)
Confidential For Internal Use Only 17
Hurler’s Syndrome (MPS-IH)
Hunter’s Syndrome (MPS-II)
Scheie Syndrome (MPS-IS)
Sanfilippo Syndrome (MPS-III)
Morquio Syndrome (MPS-IV)
Maroteaux-Lamy Syndrome (MPS-VI)
Sly Syndrome, Beta-Glucuronidase Deficiency (MPS-VII)
Adrenoleukodystrophy
Mucolipidosis II (I-cell Disease)
Krabbe Disease
Gaucher’s Disease
Niemann-Pick Disease
Wolman Disease
Metachromatic Leukodystrophy
Inherited Immune System Disorders
Ataxia-Telangiectasia
Kostmann Syndrome
Leukocyte Adhesion Deficiency
DiGeorge Syndrome
Bare Lymphocyte Syndrome
Omenn’s Syndrome
Severe Combined Immunodeficiency (SCID)
SCID with Adenosine Deaminase Deficiency
Lymphoproliferative Disorders
Non-Hodgkin’s Lymphoma
Hodgkin’s Disease
Inherited Erythrocyte Abnormalities
Beta Thalassemia Major
Sickle Cell Disease
Confidential For Internal Use Only 18
Absence of T & B Cells SCID
Absence of T Cells, Normal B Cell SCID
Common Variable Immunodeficiency
Wiskott-Aldrich Syndrome
X-Linked Lymphoproliferative Disorder
Histiocytic Disorders
Familial-Erythrophagocytic
Histiocytosis-X
Hemophagocytosis
Plasma Cell Disorders
Plasma Cell Leukemia
Waldenstrom’s Macroglobulinemia
Inherited Platelet Abnormalities
Amegakaryocytosis / Congenital Thrombocytopenia
Other Inherited Disorders
Cartilage-Hair Hypoplasia
Glanzmann Thrombasthenia
Osteopetrosis
Other Malignancies
Wing Sarcoma
Neuroblastoma
Renal Cell Carcinoma
Clinical Trial
| Status | Sponsor | Clinical Trials Gov. Identifier | |
|---|---|---|---|
| Hematologic Neoplasms Bone Marrow Failure Syndromes | Recruiting participants | University of British Columbia, Canada | NCT00897260 |
| Traumatic Brain Injury | Recruiting participants (Phase II) | The University of Texas Health Science Center, Houston, USA | NCT01251003 |
| Hematologic Malignancies | Recruiting participants (Phase II) | Fred Hutchinson Cancer Research Center, USA | NCT01175785 |
| Inborn Errors of Metabolism | Recruiting participants (Phase I) | Duke University, USA | NCT00692926 |
| Cerebral Palsy | Recruiting participants (Phase II) | Duke University, USA | NCT01147653 |
| Leukemia Lymphoma Multiple Myeloma Aplastic Anemia | Recruiting participants (Phase II) | Tufts Medical Center, USA | NCT00676806 |
| Spinal cord injuries | Recruiting participants (Phase II) | China Spinal Cord Injury Network, China | NCT01046786 |
| Hematologic Malignancies | Recruiting participants (Phase II) | Memorial Sloan-Kettering Cancer Center, USA | NCT00739141 |
| Hearing Loss | Recruiting participants (Phase I) | Memorial Hermann Healthcare System, USA | NCT01343394 |
| Hypoplastic Left Heart Syndrome |
Recruiting participants (Phase I) | Duke University, USA | NCT01445041 |
| Type 1 Diabetes | Recruiting participants (Phase I) | University of Florida, USA | NCT00873925 |
| Myelodysplastic Syndrome (MDS) Severe Aplastic Anemia (SAA) |
Recruiting participants (Phase I) | National Heart, Lung, and Blood Institute (NHLBI), USA | NCT00604201 |
Address
Cryoviva Biotech Pvt. Ltd.
129, Pace City -1,Sector-37,
Gurugram, Haryana 122001 India
Reach Us
© 2024 Cryoviva India. All rights reserved